Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Welcome to the POTP board, the DPP-IV company -- Ignore unavailable to you. Want to Upgrade?

To: dr.praveen who wrote (47)	11/18/2006 9:11:54 PM
From: rkrw	Read Replies (1) \| Respond to of 90

Sorry? Never a need to apologize. I was trying to understand mcu. And thanks to rare and you I now do. Also I don't like the aggrastat inlicense. Recurring theme in bio is the small bio thinking they can turn others trash (this one has been through mrk, glfd and mogn) and turning it into gold. Good luck to them.

To: dr.praveen who wrote (47)	11/19/2006 10:41:47 AM
From: drbio45	Respond to of 90

But the thing is the study's size and pr endpoint were acc to CK-MB of more than 50ng/ml. But when they assess it for the end point CK-MB of greater than 100ng/ml, I don't feel comfortable If you look at the previous trials in this area the marker used has always been ck-mb of 100ng/ml. Because they only used 900 patients they never thought they would see enough events using that marker so they used 50ng/ml, but all it did was cause noise because. It is remarkable that they achieved statistical significance in such a small study. The other thing that is interesting is that they had good results with both doses. They actually reduced the cardiac events by 37 percent in the 250 mg dose and 31 percent in the 750 dose so the higher dose confirmed the efficacy of the lower dose and in my opinion reduces the risk of the trial because the drug efficacy has actually been confirmed twice. The better question would be could the drug actually be more effective lest say at a 400mg dose. If they were pfizer I guess they would have the money to check that out